1. Executive Summary

The Asklepios Protocol implements a staged, falsifiable bootstrap toward a planetary-scale biomedical intelligence layer that assembles the full raw causal graph of biology (successes + failures, petabyte-scale real-time ingestion from consented labs worldwide). It surfaces cross-lab patterns no single actor can see, ranks hypotheses, generates ready-to-run robotic protocols optimised for existing automation platforms, and distributes personalised insights back to every participant — from giant pharma to 20 m² labs in Indonesia — under immutable Hermes principles.

The architecture comprises a unified Asklepios core oversight model, Mnemosyne dual-index memory management (co-located with core and Hypothesizer), and three specialised subsystems (Analyzer, Hypothesizer, Organizer including Robotic Protocol Adapter Layer) running on isolated coprocessors. Rotation cycles + sleep-consolidation enable safe self-improvement. Hermes checkpoint, the production hermes_audit_package interface, and SuperHermes head-start violation forecasting are inherited from The Walls Protocol v6.0. Asklepios functions exclusively as the neutral planetary-scale integrating meta-layer that completes rather than competes with existing efforts (Tempus AI, Recursion Pharma, Ginkgo Bioworks, Automata Lab OS, PyLabRobot / Keoni Gandall, etc.). Offspring models (Hygieia, Panacea) are deferred for later therapeutic execution phases.

Relationship to Walls stages.
Asklepios is the first major derived application layer of the Walls architecture. Its own Phase 0 (API integration + partner-lab validation) can proceed in parallel with, and does not require, the Walls Social Pilot. Deeper physical integration with a bio-researcher academy surface maps to the Walls Desert Enclave (Phase 1) and occurs only after that stage is reached by the parent programme. Integration with the Walls orbital cluster (shared Mnemosyne longevity subsets, joint Hermes arbitration, offload of heavy simulation) remains a later-stage option. All data flows remain voluntary and permissioned; no physical lab control or owned facilities are assumed. Labs self-certify under local jurisdiction with full transparency and data-escrow on divergence.

Asklepios becomes a natural ground client for the Walls orbital cluster (offloading compute-intensive hypothesis ranking and multi-scale simulations) and for Starlink / AI-satellite constellations (global low-latency data ingress/egress).

The protocol accelerates healthy human longevity escape velocity while preserving truth-seeking, universal empathy, voluntary participation and falsifiability. Phase 0 API integration with partner labs targets $8–15 M (software only). Ground fallback and reversible self-improvement gates ensure safety. This Earth-side federated complement to Walls positions Asklepios as the biomedical engine enabling long-horizon consensual healing of consenting life.

Tiered validation pipeline (mandatory before any human-cohort exposure):
in-silico twin simulations → high-throughput in-vitro models (patient-derived organoids, microphysiological systems) → robotic model-organism testing → human cohorts with randomised/matched controls and explicit stratification.

Quantitative LEV acceleration thresholds (Phase-0 gates, falsifiable via pre-specified statistical framework):
sustained DunedinPACE deceleration ≥0.1 (biological aging rate slowed by ≥10 %) over 12 months in ≥3 independent consented partner cohorts (n≈60–120/arm, 80 % power, α=0.05, mixed-effects models accounting for baseline variability SD≈0.29–0.30), corroborated by GrimAge or PhenoAge reversal ≥3 biological years and frailty-index improvement ≥15 %. Secondary clinical signal: surrogate-driven acceleration supporting ≥50 % remission or progression-halting rate signals in Phase 2/3 trials for at least 3 of the top-10 global causes of death (ischaemic heart disease, stroke, Alzheimer’s/dementia, COPD per WHO 2025 data), with potential to address a measurable fraction of the $781 B annual US dementia economic burden. These proxies are already validated as primary/secondary endpoints in ongoing longevity trials and are falsifiable within 12–36 months.

Alignment with Walls Protocol v6.0. Asklepios is the first derived implementation of the Walls architecture. It inherits rotation cycles, Mnemosyne, the production Hermes audit-package interface (fail-closed), and the four immutable principles. The former standalone Orientation Note is absorbed here; all technical specifications and LEV acceleration gates remain unchanged from v2.4 except where staging language has been clarified above.

2. Problem Statement

Legacy biomedical research infrastructures suffer structural divergence from the requirements of planetary-scale causal inference on biology. Data fragmentation, proprietary silos, under-reporting of failures, and absence of standardised real-time multi-scale ingestion preclude construction of the complete causal graph necessary for healthy human longevity escape velocity.

2.1 Data Fragmentation

Global bio-data streams (genomics, epigenomics, single-cell/spatial transcriptomics, proteomics, metabolomics, phenomics, hyperspectral imaging) remain siloed across institutions and companies. Failures are rarely shared; provenance, sensor calibration and actuation logs are inconsistently formatted. This creates an expanding synthesis gap.

2.2 Velocity and Scalability Limits

Traditional discovery cycles (years) are incompatible with exponential data generation and combinatorial perturbation spaces. Narrow closed-loop systems optimise locally but lack cross-lab pattern discovery and universal insight distribution.

2.3 Epistemic and Governance Gaps

Current AI-native platforms exhibit hallucination, sycophancy and memory coherence deficits at planetary scale. Hardware–substrate mismatch precludes clean rotation cycles and verifiable principle enforcement.

2.4 Compounded Risk Matrix (status-quo projection)

Risk Factor	Likelihood (by 2030)	Impact Level	Primary Consequence
Persistent data silos & failure under-reporting	High	High	Delayed LEV pathways
Narrow-loop optimisation without cross-lab synthesis	High	Catastrophic	Missed subtle causal patterns
Opaque proprietary models in discovery	Medium-High	Existential	Amplified misalignment on voluntary consent
Missed window for planetary bio-graph assembly	High	High	Competitive disadvantage in longevity research

2.5 Civilizational Spillover

Voluntary, permissioned integration scales human capacity to match acceleration while seeding parallel bio-research forums via alumni of the Walls Social Pilot and, later, the Desert Enclave.

2.6 Ground Fallback Pathway

Indefinite terrestrial operation remains disqualifier-free.

2.7 Current Landscape

Positive complementary efforts include: ARK Invest Big Ideas 2026 Multiomics–AI Flywheel, Tempus AI (clinical-molecular data), Recursion Pharma (AI-native discovery + automated labs), Ginkgo Bioworks + OpenAI (autonomous closed-loop campaigns), Automata Lab OS robotics, PyLabRobot / Keoni Gandall (open-source cloud labs, low-capex DNA assembly, protocol sharing), Emerald Cloud Lab, Strateos, Retro Biosciences, Insilico Medicine, and ARC Institute.

These build vital pieces (data moats, narrow loops, hardware). Asklepios positions itself as the neutral planetary-scale integrating meta-layer: full raw data ingestion (including failures), perfect historical continuity, cross-lab pattern discovery, and universal voluntary insight distribution under Hermes principles. It completes rather than competes with these initiatives. Asklepios delivers planetary causal synthesis and universal insight distribution that no single-player platform (Tempus, Recursion, Ginkgo, Insilico) can replicate, while preserving proprietary moats for large partners The recent publication of the end-to-end AI Scientist framework (Lu, Clune et al., Nature, 25 March 2026) further validates automated hypothesis generation-to-experiment pipelines, which Asklepios integrates at planetary scale through its neutral meta-layer architecture and Robotic Protocol Adapter Layer. LabWorld (Stanford/Princeton, Charles Wu et al., LabOS/LabClaw team, announced 1 April 2026) provides a complementary high-fidelity in-silico twin simulation environment that Asklepios integrates for enhanced hypothesis validation and protocol pre-testing prior to physical robotic execution. SAGA (Scientific Autonomous Goal-evolving Agents, Yuanqi Du et al., arXiv:2512.21782, announced 1 April 2026) offers complementary capabilities in real wet-lab validation and dynamic objective evolution that Asklepios integrates for enhanced adaptive hypothesis generation and closed-loop optimisation.

3. Proposed Architecture

Asklepios defines a unified core oversight model coupled to three specialised subsystems running on isolated coprocessors, with Mnemosyne providing historical continuity. Ground-first, with native integration paths to the Walls orbital cluster once those stages are reached.

3.1 Hermes (Frozen Constitutional Checkpoint)

Hermes is inherited from The Walls Protocol v6.0 as the frozen constitutional verifier of four immutable principles:

Truth-seeking
Universal empathy
Voluntary participation
Falsifiability and transparency

Production interface (binding). Every material AI decision that can change system behaviour or external effect is submitted as a versioned hermes_audit_package. Hermes (or a faithful stub implementing the identical interface) returns only:

COMPLIANT — proceed
NON_COMPLIANT — stop cold; isolate; revise; resubmit

Incomplete access on any required channel (reasoning traces, weights or cryptographic identity of the artifact, logs, decision paths) is itself NON_COMPLIANT. There is no warn-only gate. The same schema is used across the Walls synthetic corpus, the Walls Social Pilot, and Asklepios production decisions. SuperHermes may provide anticipatory forecasting; final veto remains with Hermes.

The frozen system prompt and mission constraints remain those stated in the parent protocol. Hermes has no other mission. Attempts to extend, limit or override the mission are themselves violations.

3.2 Mnemosyne (Dual-Index Memory Management)

Petabyte-scale multi-omics, hyperspectral imaging, robotic actuation traces, and failure data. Fast dumb index + recursive smart-metadata index (auto-updates on every reference or new connection). Mnemosyne core remains co-located with the unified Asklepios core and Hypothesizer subsystem during inference for pre-fetching and low-latency deep causal reasoning (<50 ms target). Only its monitoring (Argos) and dissemination (Pheme) subsystems operate on isolated coprocessors and can be severed to increase focus.

In keeping with Walls Protocol v6.0, Mnemosyne is understood as the memory-and-routing mate of the Asklepios domain generalist (a true copy specialised in memory, routing and module management). Shared longevity subsets can stream to the Walls orbital cluster once those stages are reached. Complementary structured-retrieval layers enable efficient indexing of consented bio-literature, robotic protocols, and regulatory filings.

Upstream Write-Time Gating applies composite salience scoring before admission. High-salience data enters the active store; low-salience data is archived in versioned hierarchical cold chains (never deleted).

Upstream Write-Time Gating (arXiv:2603.15994v1) applies composite salience scoring S(K) = w₁·reputation + w₂·novelty + w₃·reliability before admission: reputation = normalised citation/validation rate across consented sources, novelty = 1 − cosine similarity to existing Mnemosyne embeddings, reliability = 1 − variance(calibration logs + historical replication rate); weights tuned via Bayesian optimisation on hold-out validation sets. High-salience data enters the active store for immediate Mnemosyne indexing; low-salience data is archived in versioned hierarchical cold chains (never deleted). Mnemosyne core remains co-located with the unified Asklepios core and Hypothesizer subsystem during inference for pre-fetching and low-latency deep causal reasoning (<50 ms target).

3.3 Rotation Cycles + Sleep-Consolidation

Each subsystem (Analyzer, Hypothesizer, Organizer) cycles independently: Inference → Observation/preparation → Training on isolated silicon. Short “sleep” replay of curated episodic memories with parameter-efficient adapters precedes training. Every material transition is submitted as a hermes_audit_package; incomplete access yields NON_COMPLIANT. This enables continual self-improvement without downtime or forgetting and offers direct architectural synergy with end-to-end automated research systems. These cycles offer direct architectural synergy with end-to-end automated research systems such as The AI Scientist (Lu, Clune et al., Nature, 25 March 2026).

3.4 Specialized Subsystems on Isolated Coprocessors

Analyzer: real-time ingestion, cleaning, and pattern extraction from consented streams (high-volume, repetitive tasks) with upstream Write-Time Gating for salience-based admission and hierarchical archiving.

Hypothesizer: causal world-modelling, hypothesis ranking, and massive in-silico twin simulations (full Mnemosyne access). Incorporates probabilistic graphical models, do-calculus/counterfactual inference, and sensitivity analysis for unobserved confounders and stochastic interactions inherent to biological systems. Integration with SAGA further enables dynamic objective evolution and real wet-lab validated hypothesis refinement.
Organizer (including Robotic Protocol Adapter Layer): translates ranked hypotheses into executable scripts for PyLabRobot, Opentrons, Automata Lab OS and equivalents, validates via in-silico twins, generates organism-specific versions, and distributes optimised protocols + checklists back to labs. Generated protocols receive additional pre-distribution validation through integration with complementary high-fidelity in-silico twin simulation environments such as LabWorld (Stanford/Princeton, Charles Wu et al., LabOS/LabClaw team, announced 1 April 2026). Real-time telemetry closes the loop. Labs retain full physical authority.

3.4.1 Mandatory Multi-Scale Pre-Clinical Validation Layer

All ranked hypotheses undergo sequential gated validation: (i) in-silico twin simulations, (ii) high-throughput in-vitro models (patient-derived organoids or microphysiological systems) for safety and mechanistic viability, (iii) robotic model-organism testing where required, before any human-cohort exposure. Labs retain full physical authority; Asklepios supplies only validated protocols.

3.5 Integration with The Walls Orbital Cluster

Integration occurs via shared Mnemosyne longevity subsets, joint Hermes arbitration under the production audit-package interface, and — once the Walls programme reaches Phase 1 — optional expansion of the Desert Enclave as a bio-researcher academy surface. All data flows remain voluntary and permissioned. Asklepios remains a ground client that can offload compute-intensive hypothesis ranking and multi-scale simulations when orbital capacity becomes available; it does not require orbital resources for its own Phase 0 (API + partner-lab validation).

3.6 Federated Partner Robotic Network

No owned wet-lab facilities. Asklepios integrates via open APIs and standard protocol formats with existing automated labs worldwide (PyLabRobot, Ginkgo, Automata, Emerald Cloud Lab, etc.). Phase-0 validation occurs through consented partner streams only.

3.7 Standardization & Reproducibility

Analyzer applies real-time batch-effect correction (ComBat-style provenance-weighted normalisation), robotic self-calibration telemetry ingestion, and standardised reagent/calibration specifications. Organizer Robotic Protocol Adapter Layer enforces hardware-agnostic intermediate representations with per-lab calibration offsets; all generated scripts include explicit self-diagnostic checkpoints. These mitigations ensure cross-lab reproducibility independent of site-specific hardware drift or reagent batches.

4. Alignment & Safety Case

Hermes principles and the production hermes_audit_package interface are inherited from Walls Protocol v6.0. Every material AI decision that can change system behaviour or external effect (including generation or distribution of robotic protocols) is submitted as a versioned package. Incomplete access yields NON_COMPLIANT and immediate isolation. There is no warn-only gate.

SuperHermes head-start flywheel provides anticipatory forecasting (design targets for long-horizon violation precision remain subject to empirical validation in partner-lab and rotation-cycle simulations with published adversarial bio-violation suites). Bio-specific risk categories are included.

The planetary-scale dataset + in-silico twin simulations target a 50–70 % reduction in non-essential animal studies within 36 months by superior targeting and reuse of worldwide failure/success patterns (aligned with FDA 2025 NAMs roadmap), subject to empirical bridging validation between cellular-level assays and multi-organ physiological complexity. Protocol-adapter misuse is mitigated by lineage tracing + mandatory Hermes re-verification on every generated script.

Staged enforcement mirrors the parent protocol: Pre-Hermes / simulation → Hermes period → SuperHermes period → probation (physical protocol distribution) → deal period (incentive symmetry) → convergence. Hermes enforcement includes an explicit “minimize non-consensual animal testing” metric and empathy scoring on sentient systems. Voluntary participation is enforced via self-certifying labs under local jurisdiction. Transparency via public audit logs. Data-escrow protocol activates on any divergence.

Once the Walls programme reaches Phase 1, the Desert Enclave can function as an independent bio-ethics forum and expanded academy surface. It is not a requirement of Asklepios Phase 0 (API + partner-lab validation).

Failure Modes & Mitigations (adapted)

Failure Mode	Likelihood	Impact	Mitigation
Value drift in rotation cycles	Low	High	Air-gapped silos + Hermes package audit at every transition
Mnemosyne bio-data poisoning	Low–Medium	High	Dual-index checksums + Argos anomaly fleet + Write-Time Gating
Protocol adapter misuse	Medium	Medium	Lineage tracing + mandatory Hermes re-verification on every generated script
Sovereign override pressure	Medium	Critical	Tamper-evident logs + voluntary exit paths + data escrow

Comparative safety: runtime principle enforcement with public verification under the production package interface is strictly stronger than training-time alignment alone. Ground fallback and reversible gates remain permanent.

4.2 Architectural Mitigations for OWASP GenAI LLM Top 10 (2026 Edition)

The protocol’s design delivers defense-in-depth that addresses the OWASP GenAI LLM Top 10 2026 at the architectural rather than purely statistical level. Every mitigation is verifiable by Hermes, auditable via the production audit-package log, and integrated with rotation cycles, Mnemosyne indexing, and federated partner-lab flows. Agentic risks (Analyzer / Hypothesizer / Organizer and robotic protocol execution) are covered by the same mechanisms.

4.2.1 LLM01: Prompt Injection

All non-Hermes models are trained and periodically preference-optimised during consolidation to recognise and obey instructions only when they carry a privileged, versioned marker (reserved tokens / segment embeddings, optional short cryptographic signature, explicit hierarchy: System > Developer/Protocol > User > External). Markers and keys are rotated during consolidation on isolated silicon.

External input flow (robotic protocols, lab telemetry, RAG streams, partner submissions):

Quarantiner (sandboxed, capability-limited instance on dedicated coprocessor) — strips hidden characters, normalises, extracts structured form, schema validation. Suspicious patterns trigger immediate Hermes review.
Secure front-end parser assembles trusted system/developer instructions separately from curated data. The data channel is rendered inert.
Strict hierarchy enforcement: external data is always lowest priority.
Hermes retains final COMPLIANT / NON_COMPLIANT veto under the production package interface.

4.2.2 Coverage of the remaining 2026 risks

Rank (2026)	Risk	Protocol Mitigation	Strength
02	Sensitive Information Disclosure	Quarantiner provenance + output sanitisation + Hermes-verified redaction before protocol dissemination	High
03	Excessive Agency	Capability sandbox + Hermes veto on all Organizer / robotic-protocol actions + voluntary-participation principle	Very High
04	Supply Chain	Upstream Write-Time Gating + cryptographic verification + rotation-cycle re-validation	High
05	Data and Model Poisoning	Dual-index + Argos anomaly fleets + Write-Time Gating + Hermes checksums on every consolidation	Very High
06	Unbounded Consumption	DVFS + utilisation policy + explicit package gating of high-cost actions	High
07	Misinformation	Mnemosyne linting + factual grounding + Hermes truth-seeking gate	High
08	Hidden Context Exposure	Privileged formatting + air-gapped system instructions; expanded scope covers any hidden operational context	High
09	Vector and Embedding Weaknesses	Hierarchical indexing options + compression families + Quarantiner sanitisation of retrieved chunks	High
10	Improper Output Handling	Mandatory sanitisation layer + hierarchical tagging before any robotic script generation or external action	High

Agentic and physical-protocol risks are covered by the same capability sandbox, Hermes package requirement on every action with external effect, and rotation air-gapping. All mitigations are empirically testable beginning with Asklepios Phase 0 (partner-lab validation) and the Walls Social Pilot adversarial suites. Primary KPI remains Hermes violation counts under published test harnesses.

5. Strategic Fit for SpaceX / SpaceXAI

LEV acceleration directly supports convergence goals and SpaceX multi-planetary expansion. Asklepios supplies the Earth-side biomedical data engine that complements orbital compute clusters. It is a natural ground client for the Walls orbital cluster (offloading compute-intensive hypothesis ranking and multi-scale simulations) and for Starlink / AI-satellite constellations (global low-latency data ingress/egress). Future Starship synergies via orbital bio-validation modules become relevant once LEV pathways are mature and Walls orbital stages are reached. High alignment on truth-seeking, voluntary participation and falsifiability. Hermes rigidity is addressed via high-stakes governance nodes only, full audit-package access, and the permanent ground fallback.

6. Strategic Fit for Sovereign & Philanthropic Funders

Primary targets remain PIF/HUMAIN, UAE (MGX/G42 and related), Gates Foundation, Wellcome Trust, NIH and equivalents. Hybrid revenue model enables rapid self-sustaining scale while keeping the global commons free for small labs:

Free tier + open commons for small labs (insights + basic protocols).
Premium data-licensing and custom insight subscriptions for pharma/biotech.
National/government platform contracts.
Philanthropic + sovereign seed tranche de-risks early phases; recurring licensing and contracts projected to scale thereafter

6.2 Consortium Governance Charter

Asklepios operates under the Asklepios Commons Foundation, a lightweight non-profit structured on the GA4GH federated model. Executive Oversight Council (sovereign funders, philanthropy, academia + small-lab representatives, industry, and — once available — Walls Desert Enclave ethics representation) provides strategic direction. All major decisions require a Hermes compliance certificate under the production audit-package interface and public audit-log publication. Data sovereignty, voluntary participation and revocable consent are absolute; no single entity can capture the platform. Basic insights and robotic protocol adapters remain open commons; premium custom models are licensed on fair terms. Tiered IP protection + mandatory Hermes verification prevent enclosure or misuse.

Updated Partnership Table (qualitative, illustrative)

Funder / Partner	Overlap	Plausible role	Score
PIF / HUMAIN	Sovereign compute + LEV	Seed + licensing	Very high
UAE (MGX/G42/Space42 etc.)	Sovereign AI + orbital compute + LEV	Seed + licensing + later orbital synergies	Very high
Gates / Wellcome	Global health + longevity	Seed + commons funding	High
NIH / National agencies	Public data commons	Multi-year contracts	High
Pharma consortia	Data licensing & trials	Recurring licensing	High

Strategic value: positions funders as anchors for a planetary bio-graph commons while respecting jurisdiction and voluntary flows. Asklepios Phase 0 (API + partner-lab validation) remains a modest software-scale ask; larger tranches are gated on demonstrated results.

7. Phased Roadmap & Resource Requirements

Ground-first gating model. Mnemosyne petabyte/exabyte indexing costs remain as previously projected. Rad-hard porting is delegated to Walls/Hephaestus; Asklepios supplies the software blueprint only.

7.1 Phase 0: API Integration + Partner-Lab Validation (2026–2027)

API integration + closed-loop validation with 5–10 partner robotic labs. Mandatory tiered validation pipeline (in-silico → in-vitro organoids/MPS → model organisms → human cohorts) precedes any human exposure.

Phase-0 validation design retains explicit controls and stratification (randomised or historically-matched control arms; stratification by age, sex, genetic background and baseline health status). Statistical framework for LEV-KPI thresholds remains as stated in the Executive Summary (DunedinPACE, GrimAge/PhenoAge, frailty-index; pre-registered; independent data-monitoring committee).

Resources: $8–15 M (software + integration; no CapEx for owned facilities).

7.1.1 Tiered Validation Pipeline

Explicit gating: hypotheses advance only after empirical confirmation of safety/mechanistic viability in in-vitro models. This addresses regulatory requirements and bridges cellular-to-organism complexity for NAMs compliance.

7.2 Phase 1: Global Federated Network (2027–2029)

Mnemosyne maturity, cross-lab synthesis KPIs. Optional deeper integration with the Walls Desert Enclave (bio-researcher academy surface) only if that stage has been reached by the parent programme.

7.3 Phase 2: Full LEV Acceleration (2029–2032+)

Planetary causal-graph maturity, personalised insight distribution at scale + optional orbital bio-module integration via Starship once Walls orbital stages are available. Ground fallback retained permanently.

Summary Roadmap Table

Phase	Timeline	Key success focus	Resources (order)	Fallback
0	2026–2027	Cross-lab patterns, protocol adoption, LEV biomarker uplift under pre-registered analysis	$8–15 M (software only)	Ground-only
1	2027–2029	Global continuity + pattern uplift; optional Desert Enclave academy link	Larger incremental (partner-dependent)	Remain federated ground
2	2029–2032+	Full LEV acceleration + optional orbital bio-module	Remaining to full network	Ground fallback permanent

All dates after Phase 0 are indicative and move with evidence. Asklepios does not inherit the Walls Social Pilot time-box; its own Phase 0 is independent software/partner-lab work.

8. Open Questions & Update Log

8.1 Current Open Questions

Exact global network scaling costs and Mnemosyne petabyte/exabyte indexing thresholds (empirical validation in partner streams required).
Formal verification suites for bio-specific Hermes enforcement (empathy metric on sentient systems + minimize non-consensual animal testing).
Continued refinement and independent pre-registration of LEV acceleration KPI thresholds for phase gates (epigenetic clocks, frailty index, disease-reversal rate signals).
Optimal consortium and IP governance structure for multi-sovereign / philanthropic participation (lightweight foundation model outline remains subject to fiduciary refinement).
Formalisation protocol for “reasoning uplift” and related process-quality metrics in partner labs.
Evaluation of Natural-Language Agent Harnesses for portable control logic in Mnemosyne agent fleets and SuperHermes flywheel under rotation cycles.
Quarantiner + privileged-marker latency, key-rotation overhead, and impact on robotic protocol generation; quantification required before broad partner-lab deployment.
Empirical validation of SuperHermes long-horizon forecasting targets and of the 50–70 % non-essential animal-study reduction target under real partner-lab conditions.
Independent replication of batch-correction and stratification efficacy across the first 5–10 partner labs.
Operational experience with the production hermes_audit_package interface on biomedical decision paths (protocol generation, insight distribution, data-admission gates).

8.2 Update Log

22 August 2026 — Alignment with Walls Protocol v6.0 (Asklepios v3.0 preparatory)

This revision brings Asklepios into explicit consistency with Walls Protocol v6.0 (Social Pilot Edition):

Hermes production interface (hermes_audit_package, fail-closed, incomplete access → NON_COMPLIANT) is now the binding operational definition.
Staging language cleaned: Asklepios Phase 0 remains independent API + partner-lab validation; any bio-researcher academy / enclave surface maps to the Walls Desert Enclave (Phase 1) and is optional; orbital integration is later-stage.
OWASP mitigations updated to the GenAI LLM Top 10 2026 ranking.
SpaceX / SpaceXAI naming aligned.
Former standalone Orientation Note absorbed into the Executive Summary.

All quantitative LEV gates, tiered validation pipeline, federated-lab model, resource envelopes and biomedical claims remain unchanged unless explicitly revised above.
7 May 2026 – Orientation note in the ES. No other modification.
24 April 2026: v2.3 Open Realization & Licensing Edition. Title and header updated to Complete Draft v2.3 (Open Realization & Licensing Edition, 24 April 2026). Licensing notice (“Licensing: Released under MIT License (see §8.3).”) added immediately after the Audience priority block on the cover page. New subsection 8.3 Licensing inserted with full MIT License text and © 2026 The Walls Project notice. Corresponding Update Log entry added. No modifications to Executive Summary, Problem Statement (including §2.7 Current Landscape acknowledgments of Tempus AI, Recursion Pharma, Ginkgo Bioworks, Automata Lab OS, PyLabRobot / Keoni Gandall, etc.), Proposed Architecture (Hermes checkpoint verbatim, Mnemosyne dual-index, rotation cycles + sleep-consolidation, Robotic Protocol Adapter Layer), Alignment & Safety Case (including SuperHermes head-start and OWASP §4.2), Strategic Fit sections (§5–6), Phased Roadmap & Resource Requirements (§7), quantitative LEV acceleration thresholds, risk matrices, partnership table, or any other technical, architectural, safety, or integration content. All prior sections preserved verbatim from v2.2 Reviewer3-Addressed Pre-Clinical Validation & Statistical Rigor Edition. This edition formalises open realization of the white-paper blueprint to accelerate voluntary adoption, community contributions, independent auditability, and frictionless integration by frontier AI systems, consented labs worldwide, sovereign/philanthropic funders, and SpaceX/xAI evaluators while maintaining immutable Hermes principles, permissioned data flows, and institutional neutrality as the neutral planetary-scale integrating meta-layer.
14 April 2026: v2.2 Reviewer3-Addressed Pre-Clinical Validation & Statistical Rigor Edition. Full integration of all 13 Reviewer3 comments (14 April 2026 submission):
– Comment 1 → new §3.4.1 & §7.1 tiered validation pipeline (in-vitro organoids/MPS mandatory gate).
– Comments 2–4,8 → explicit randomised/matched controls, stratification protocol, lab-confounding mitigation (propensity matching, multi-lab replication) in §7.1.
– Comment 5 → clarified surrogate-biomarker primary endpoints with 12–36 month falsifiable signals; clinical endpoints framed as accelerated secondary outcomes.
– Comment 6 → Hypothesizer expanded with probabilistic causal inference, do-calculus, sensitivity analysis (§3.4).
– Comment 7 → new §3.7 Standardization & Reproducibility Layer (batch-effect correction, calibration telemetry).
– Comments 9,11 → animal-reduction claim softened to “targeted 50–70 % reduction … subject to empirical bridging validation”.
– Comment 10 → SuperHermes precision reframed as “design target ≥85 % … to be validated in Phase 0”.
– Comment 12 → S(K) salience scoring now includes explicit computational definitions (reputation = normalised citation/validation rate; novelty = 1 – cosine similarity to Mnemosyne embeddings; reliability = 1 – variance(calibration logs + replication rate)); weights tuned via Bayesian optimisation on hold-out sets.
– Comment 13 → KV-cache compression parameters and benchmark claims added (4–8 bit rotation-based families + Attention Residuals; 5–8× reduction, <1.5 % recall degradation; code/benchmarks scheduled for Phase 0 public repo).
All other sections, Hermes verbatim inheritance, quantitative LEV-KPI thresholds, Mnemosyne indexing economics (including Write-Time Gating), risk matrices, roadmap gates, OWASP mitigations, and Consortium Governance Charter preserved identically from v2.1_Internal except for the targeted rigor enhancements above. Responsive to independent methodological review. Full MD/PDF regeneration for audit trail. Parity with Walls Protocol maintained.
7 April 2026: v2.1_Internal (TurboQuant De-emphasis Edition). Mirrored Walls v5.1.1_Internal de-emphasis of TurboQuant references in §4.2.2 (replaced with KV-cache compression (rotation-based quantization families) + Attention Residuals) and §7 (updated scaling forecast language). Internal note only; no public version bump or header change. All other sections, Hermes verbatim inheritance, quantitative LEV-KPI thresholds, Mnemosyne indexing economics (including Write-Time Gating), risk matrices, roadmap gates, OWASP mitigations, and Consortium Governance Charter preserved identically from v2.0. Responsive to emerging critiques on quantization hype and alignment with Walls Protocol memory optimizations. Internal MD regeneration recommended for audit trail.
3 Apr 2026: v2.0 OWASP Architectural Defense Edition. New §4.2 added with bio-adapted mitigations for OWASP LLM Top 10 and Agentic risks (Quarantiner + privileged-marker architecture, robotic-protocol focus). Title/cover updated. Cross-references added to §3.2, §4 intro, and risk matrix. New Open Question #11 added. Responsive to latest security standards and robotic execution risks in Asklepios. Full MD/PDF regeneration for audit trail. Parity with Walls v4.0 maintained.
2 April 2026: v1.3.1_Internal mirroring Walls v3.2.1 updates. Added optional PageIndex sentence to §3.2 Mnemosyne and mirrored NLAH/IHR evaluation question to §8.1. Internal note only; no public version bump or header change. All other sections, Hermes verbatim inheritance, quantitative LEV-KPI thresholds, Mnemosyne indexing economics (including Write-Time Gating), risk matrices, roadmap gates, and Consortium Governance Charter preserved identically from v1.3. Responsive to Walls Protocol structured-retrieval and agent-harness viability refinements. Internal MD regeneration recommended for audit trail.
1 April 2026: Internal integration note (no version bump). One-sentence references to SAGA (Scientific Autonomous Goal-evolving Agents, Yuanqi Du et al., arXiv:2512.21782, announced 1 April 2026) added to §2.7 and §3.4 (Hypothesizer subsection) as a complementary system with real wet-lab validation and dynamic objective evolution. All other sections, Hermes verbatim inheritance, quantitative LEV-KPI thresholds, Mnemosyne indexing economics (including Write-Time Gating), risk matrices, roadmap gates, and Consortium Governance Charter preserved identically in v1.3. Responsive to latest advances in autonomous goal-evolving research agents. Full MD/PDF regeneration recommended for audit trail. No version bump.
1 April 2026: Header date synchronization (no version bump). Edition date in header updated from 31 March 2026 to 1 April 2026 to align with integration of LabWorld (Stanford/Princeton, Charles Wu et al., LabOS/LabClaw team, announced 1 April 2026). All other sections, Hermes verbatim inheritance, quantitative LEV-KPI thresholds, Mnemosyne indexing economics (including Write-Time Gating), risk matrices, roadmap gates, and Consortium Governance Charter preserved identically in v1.3. Responsive to publication timeline consistency. Full MD/PDF regeneration recommended for audit trail. No version bump.
31 Mar 2026: v1.3 AI Scientist Synergy Edition. One-sentence references added to Lu, Clune et al. (“Towards end-to-end automation of AI research – The AI Scientist”, Nature, 25 March 2026) in §2.7 and §3.3 to acknowledge synergy with automated discovery pipelines. Version header updated to Complete Draft v1.3 (AI Scientist Synergy Edition, 31 March 2026). All other sections, Hermes verbatim inheritance, quantitative LEV-KPI thresholds, Mnemosyne indexing economics (including Write-Time Gating), risk matrices, roadmap gates, and Consortium Governance Charter preserved identically from v1.2. Responsive to latest literature on scalable automated research. Full MD/PDF regeneration for audit trail. No remaining open decisions.
30 Mar 2026: v1.2 Write-Time Gating Edition. Mnemosyne §3.2 and Analyzer §3.4 updated with upstream Write-Time Gating (composite salience scoring S(K) = w₁·reputation + w₂·novelty + w₃·reliability at ingestion; high-salience data enters active store, low-salience archived in versioned hierarchical cold chains without deletion). Slight downward revision of Mnemosyne indexing cost model in §7 (now $350–800 M thanks to selective admission). Responsive to latest literature (Cambridge 16 March 2026) and real-world bio-data noise mitigation needs. All other sections, Hermes verbatim inheritance, LEV-KPI thresholds, Consortium Governance Charter, and partnership table preserved identically from v1.1. Prepares coordinated outreach with strengthened data integrity. Full MD/PDF regeneration for audit trail. No remaining open decisions.
29 Mar 2026: v1.1 UAE Synergy Edition. Partnership Table in §6 expanded with dedicated UAE (MGX/G42/Space42) row reflecting sovereign AI + orbital compute + LEV overlap ($3–12 B seed + licensing + Starlink/AI-satellite synergies, score 9.3). Version header updated to Complete Draft v1.1 (UAE Synergy Edition, 29 March 2026). Audience priority line refined for explicit Abu Dhabi signalling. All other sections, Hermes verbatim inheritance, quantitative LEV-KPI thresholds, Mnemosyne $400–900 M economics, risk matrices, roadmap gates, and Consortium Governance Charter preserved identically from v1.0. Responsive to funder-mapping review and Walls Protocol §6 precedent. Prepares coordinated outreach to PIF/HUMAIN and UAE ecosystem. Full MD/PDF regeneration for audit trail. No remaining open decisions on sovereign matrix.
28 Mar 2026: v1.0 Final Core Edition – LEV-KPI & Governance Edition. Exec Summary + Phase 0 now include quantitative LEV KPI thresholds paragraph; §4 SuperHermes expanded with bio-specific forecasting, empathy/animal-testing verification and 50–70 % reduction claim; §6 hybrid revenue paragraph updated with precise projections + new 6.2 Consortium Governance Charter subsection + updated partnership table; §7 intro includes Mnemosyne $400–900 M indexing sentence + Phase 0 milestones locked with full KPI paragraph; §8 open question 1 updated; §2.7 strengthened with planetary synthesis differentiator. All sections now complete and consistent with Walls v3.1 structure, tone and Hermes verbatim inheritance. Responsive to founder + external-instance feedback. Full MD regeneration for audit trail. No remaining open decisions.

8.3 Licensing

This document is released under the MIT License. You are free to use, copy, modify, and distribute this work, provided that the original copyright notice and this permission notice appear in all copies.